Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90

Blood

Volumn 97, Issue 12, 2001, Pages 3699-3706

  Seidemann, Kathrin ^a,b,c,d,e,f   Tiemann, Markus ^a,b,c,d,e,f   Schrappe, Martin ^a,b,c,d,e,f   Yakisan, Elif ^a,b,c,d,e,f   Simonitsch, Ingrid ^a,b,c,d,e,f   Janka Schaub, Gritta ^a,b,c,d,e,f   Dörffel, Wolfgang ^a,b,c,d,e,f   Zimmermann, Martin ^a,b,c,d,e,f   Mann, Georg ^a,b,c,d,e,f   Gadner, Helmut ^a,b,c,d,e,f   Parwaresch, Reza ^a,b,c,d,e,f   Riehm, Hansjörg ^a,b,c,d,e,f   Reiter, Alfred ^a,b,c,d,e,f  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d HELIOS KLINIKUM BERLIN BUCH   (Germany)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; OXAZAPHORIN; PREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; FEMALE; GERMANY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0035877999     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.12.3699     Document Type: Article

References (45)

1. Stein H, Mason DY, Gerdes J. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848-858.
2. Kadin ME. Primary Ki-1-positive anaplastic large-cell lymphoma: a distinct clinicopathologic entity. Ann Oncol. 1994;5(suppl 1):25-30.
3. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
4. Lennert K, Feller AC. Histopathologie der Non-Hodgkin-Lymphome. Berlin, Germany: Springer; 1990.
5. Stansfeld AG, Diebold J, Kapanci Y, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292-292.
6. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998;91:2076-2084.
7. De Bruin PC, Gruss HJ, Van Der Valk P, Willemze R, Meijer CJ. CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications. Leukemia. 1995;9:1620-1627.
8. Jaffe ES, Krenacs L, Raffeld M. Classification of T-cell and NK-cell neoplasms based on the REAL classification. Ann Oncol. 1997;8:17-24.
9. De Bruin PC, Beljaards RC, van Heerde P, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology. 1993;23:127-135.
10. Nakagawa A, Nakamura S, Ito M, Shiota M, Mori S, Suchi T. CD30-positive anaplastic large cell lymphoma in childhood: expression of p80npm/alk and absence of Epstein-Barr virus. Mod Pathol. 1997;10:210-215.
11. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995;86:1954-1960.
12. Pittaluga S, Wiodarska I, Pulford K, et al. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol. 1997;151:343-351.
13. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997;89:1394-1404.
14. Sarris AH, Luthra R, Papadimitracopoulou V, et al. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Blood. 1996;88:1771-1779.
15. Downing JR, Shurtleff SA, Zielenska M, et al. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptasepolymerase chain reaction. Blood. 1995;85:3416-3422.
16. Lamant L, Meggetto F, al Saati T, et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease: comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood. 1996;87:284-291.
17. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Münster studies. J Clin Oncol. 1994;12:899-908.
18. Sandlund JT, Pui C-H, Roberts WM, et al. Clinicopathological features and treatment outcome of children with large-cell anaplastic lymphoma and the t(2;5)(p23;q35). Blood. 1994;84:2467-2471.
19. Brugières L, Le Deley MC, Pacquement H, et al. CD30+ anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;10:3591-3598.
20. Vecchi V, Burnelli R, Pileri S, et al. Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood. Med Pediatr Oncol. 1993;21:402-410.
21. Massimino M, Gasparini M, Giardini R. Ki-1 (CD30) anaplastic large-cell lymphoma in children. Ann Oncol. 1995;6:915-920.
22. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage - a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol. 1995;13:359-372.
23. Pileri S, Falini B, Delsol G, et al. Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD 30+/Ki-1+ with a high content of reactive histiocytes). Histopathology. 1990;16:383-391.
24. Hsu SM, Raine L, Fanger H. Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
25. Cordell JL, Falini B, Erber WN. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal antialkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984;32:219-229.
26. Anagnostopoulos I, Hummel M, Kreschel C, Stein H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood. 1995;85:744-750.
27. Hansmann ML, Wacker HH, Gralla J, et al. Ki-B5: a monoclonal antibody unrelated to CD45 recognizes normal and neoplastic B-cells in routine paraffin sections. Blood. 1991;77:809-817.
28. Mason DY, Cordell J, Brown M, et al. Detection of T-cells in paraffin wax embeddeed tissue using antibodies against a peptide sequence from the CD3 antigen. J Clin Pathol. 1989;42:1194-1200.
29. Schwarting R, Gerdes J, Durkop H, Falini B, Pileri S, Stein H. BerH2: a new anti-Ki1 (CD30) monoclonal antibody directed at a formalin-resistant epitope. Blood. 1989;74:1678-1689.
30. Murphy SB. Classification, staging and end results of treatment in childhood non-Hodgkin's lymphoma: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7:332-339,
31. Lister TA, Crowther D, Sutcliffe SB. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630-1636.
32. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
33. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
34. Greenwood M. A report on the natural duration of cancer. Rep Public Health Med Subj. 1926;33:1-26.
35. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
36. Massimino M, Gasparini M, Giardini R. Ki-1 (CD30) anaplastic large cell lymphoma in children. Ann Oncol. 1999;6:915-920.
37. Anderson JR, Jenkin RD, Wilson JF, et al. Longterm follow-up of patients treated with COMP or LSAL2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol. 1993;11:1024-1032.
38. Hutchison RE, Berard CW, Shuster JJ, Link MP, Pick TE, Murphy SB. B-cell lineage confers a favorable outcome among children and adolescents with large-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol. 1995;13:2023-2032.
39. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med. 1996;334:1238-1248.
40. Kaatsch U, Kaletsch U, Michaelis J. Annual report 1997 of the German Childhood Cancer Registry. Mainz, Germany: Academic; 1998.
41. Sandlund JT, Pui C-H, Santana VM, et al. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma. J Clin Oncol. 1994;12:895-898.
42. Rubie H, Gladieff L, Robert A, et al. Childhood anaplastic large cell lymphoma Ki-1/CD30: clinicopathologic features of 19 cases. Med Pediatr Oncol. 1994;22:155-161.
43. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol. 1993;11:1208-1212.
44. Ingram L, Mott MG, Mann JR, et al. Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia with the UKCCSG regimens. Br J Cancer. 1987;55:463-466.
45. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334:745-750.